Tuesday, 28 Jan 2020

You are here

Two vs. Four Weeks of Antibiotic Therapy in Septic Arthritis

A prospective trial has shown that 2 weeks of antibiotic therapy is as effective as 4 weeks of antibiotic therapy, with similar outcomes but shorter hospital stays.

This Swiss study was a prospective, unblinded, randomised, non-inferiority study comparing either 2 or 4 weeks of antibiotic therapy after surgical drainage of native joint bacterial arthritis in adults. 

A total of 154 cases were enrolled (77 in each arm) and underwent surgical lavage prior to antibiotic therapy.

The cure rates were 99% in the 2-week arm and 97% in the 4-week arm. There was no difference in the number of adverse events or sequelae between the study arms. Recurrence rates were infrequent and equal between groups (1 vs. 2).

All antibiotics were given intravenously (eg, co-amoxiclav; cefazolin; cefuroxime; cefepime; ertapenem; imipenem; piperacillin/tazobactam; vancomycin; or daptomycin) and refined after culture and sensitivity results.  Patients were switched to oral therapy at the discretion of the treating clinicians.

Of the 154 arthritis cases, 99 were for bacterial infection of the hand and wrist.  Bacteremia was seen in 4% of cases and intraarticular crystals were found in 4% of patients.

In this study, two weeks of targeted antibiotic therapy is not inferior to 4 weeks regarding cure rate, adverse events or sequelae and leads to a significantly shorter hospital stay, at least for hand and wrist arthritis.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

2019 EULAR Recommendations for the Management of Rheumatoid Arthritis

The 2019 update to the EULAR recommendations on the use of synthetic and biological disease-modifying antirheumatic drugs in rheumatoid arthritis (RA) have been published in Annals of Rheumatic Disease - highlighting the efforts of an international consensus committee effort. In the end, the task force put forth 5 overarching principles and 12 recommendations concerning use of conventional synthetic DMARDs, glucocorticoids, biological DMARDs, biosimilar DMARDs, and targeted synthetic DMARDs (the Janus kinase (JAK) inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib).

Low Risk of Inflammatory Arthritis in Hidradenitis Suppurativa Patients

JAMA Dermatology reports that after the onset and diagnosis of hidradenitis suppurativa (HS), such patients have a higher risk of certain forms inflammatory arthritis.

Best of 2019 - War on RA - Part 1: Walk on the Moon

It’s a great time to be a rheumatologist and to manage RA. But, if you keep doing what you’re doing, you’re going to keep getting what you’ve got.

Best of 2019 - War on RA - Part 3: Useless Drugs

We have options that are endless – we have 28 biologics in rheumatology; 19 approved for RA in the last 20 years, but 15 of these are me-too copies or biosimilars. We currently have 2 JAK inhibitors and may have 3 or 4 by year end. But what we really need is the right drug, at the right time, in the right patient – but how will we know.

Link Between Obstructive Lung Disease and Developing RA?

We all know that the microbiome in the gut may be very important for multiple immune diseases. However, new findings from the ACR, 2019 in Atlanta reinforce how important the interface is between the lungs and developing rheumatoid arthritis.